Houde, M., Ince, H., Abizaid, A., Toelg, R., Lemos, P.A., et al. (2015) Safety and Performance of the Second-Generation Drug-Eluting Absorbable Metal Scaffold in Patients with De-Novo Coronary Artery Lesions (BIOSOLVE-II): 6 Month Results of a Prospective, Multicenter, Non-Randomised, First-in-Man Trial. The Lancet, 387, 31-39.
http://dx.doi.org/10.1016/S0140-6736(15)00447-X

has been cited by the following article:

• TITLE: Reduction in the Corrosion Rate of Magnesium and Magnesium Alloy Specimens and Implications for Plain Fully Bioresorbable Coronary Artery Stents: A Review

  AUTHORS: Gladius Lewis

  KEYWORDS: Coronary Artery Disease, Fully Bioresorbable Stents (FBRSs)

  JOURNAL NAME: World Journal of Engineering and Technology, Vol.4 No.4, November 9, 2016

  ABSTRACT: The most popular treatment/management modality for coronary artery disease, which is one of the leading causes of death, is percutaneous transluminal coronary intervention (popularly known as “plain old balloon angioplasty”) followed by implantation of a stent (“stenting”). Stent types have evolved from bare metal stents through first-generation drug-eluting stents to fully bioresorbable stents (FBRSs). Two examples of FBRSs are 1) Mg scaffold with no coating; and 2) Mg alloy scaffold coated with a bioresorbable polymer in which an anti-proliferative drug is embedded. In the case of Mg/Mg alloy FBRSs, one of the reported clinical results is that the resorption time of the stent is too short (in vivo resorption time (and, hence, improving the clinical efficacy) of the current generation of fully-bioresorbable Mg/Mg-alloy stents as well as guide the development of the next generation of these stents.